Macrogenics Inc
M55
Company Profile
Business description
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
Contact
9704 Medical Center Drive
RockvilleMD20850
USAT: +1 301 251-5172
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
339
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,157.90 | 0.80 | -0.01% |
| CAC 40 | 8,087.12 | 44.17 | 0.55% |
| DAX 40 | 23,044.60 | 152.92 | 0.67% |
| Dow JONES (US) | 41,985.35 | 32.03 | 0.08% |
| FTSE 100 | 8,689.16 | 42.37 | 0.49% |
| HKSE | 23,905.56 | 215.84 | 0.91% |
| NASDAQ | 17,784.05 | 92.42 | 0.52% |
| Nikkei 225 | 37,608.49 | 68.57 | -0.18% |
| NZX 50 Index | 12,128.21 | 14.67 | 0.12% |
| S&P 500 | 5,667.56 | 4.67 | 0.08% |
| S&P/ASX 200 | 7,936.90 | 5.70 | 0.07% |
| SSE Composite Index | 3,370.03 | 5.20 | 0.15% |